Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

NEURODEGENERATION

Dominantly inherited Alzheimer’s disease: a compass for drug development

Nature Medicine volume 27, pages 1148–1150 (2021)Cite this article

Subjects

The first phase 3 trial of amyloid-β-targeting monoclonal antibodies in dominantly inherited Alzheimer’s disease failed to slow cognitive decline in patients. Could it still help to inform future study design and drug development in this setting?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Positron emission tomography with the Aβ radiotracer 11C-PiB.

Leonardo Iaccarino, University of California San Francisco, and G. R.

References

  1. Bateman, R. J. et al. Alzheimers Res. Ther. 3, 1 (2011).

    Article  Google Scholar 

  2. Hardy, J. & Selkoe, D. J. Science 297, 353–356 (2002).

    Article  CAS  Google Scholar 

  3. Bateman, R. J. et al. N. Engl. J. Med. 367, 795–804 (2012).

    Article  CAS  Google Scholar 

  4. Fleisher, A. S. et al. Lancet Neurol. 11, 1057–1065 (2012).

    Article  CAS  Google Scholar 

  5. Salloway, S. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01369-8 (2021).

  6. Ringman, J. M. et al. J. Neuropathol. Exp. Neurol. 75, 284–290 (2016).

    Article  CAS  Google Scholar 

  7. VandeVrede, L. et al. Alzheimers Dement. (Amst.) 12, e12101 (2020).

    Google Scholar 

  8. Mintun, M. A. et al. N. Engl. J. Med. 384, 1691–1704 (2021).

    Article  CAS  Google Scholar 

  9. Knopman, D. S., Jones, D. T. & Greicius, M. D. Alzheimers Dement. 17, 696–701 (2021).

    Article  Google Scholar 

  10. Strobel, G. Alzforum https://www.alzforum.org/news/research-news/aiming-tangles-heart-dian-tu-trial-torpedo-taus-core (2021).

  11. Cummings, J., Lee, G., Ritter, A., Sabbagh, M. & Zhong, K. Alzheimers Dement. (NY) 6, e12050 (2020).

    Google Scholar 

  12. Apostolova, L.G. et al. Alzheimers Dement. https://doi.org/10.1002/alz.12350 (2021).

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of California San Francisco, San Francisco, CA, USA

    Gil D. Rabinovici

  2. Department of Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA

    Gil D. Rabinovici

  3. Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA

    Gil D. Rabinovici

Authors
  1. Gil D. Rabinovici
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gil D. Rabinovici.

Ethics declarations

Competing interests

G.D.R. receives research support from Avid Radiopharmaceuticals, General Electric Healthcare, Genentech and Life Molecular Imaging; has served on scientific advisory boards for Axon Neurosciences, Eisai, Genentech and F. Hoffman-La Roche; and serves on a data safety monitoring board for Johnson & Johnson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rabinovici, G.D. Dominantly inherited Alzheimer’s disease: a compass for drug development. Nat Med 27, 1148–1150 (2021). https://doi.org/10.1038/s41591-021-01434-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01434-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing